Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Wall Street analysts sharply upgraded their outlook on Nektar Therapeutics on Wednesday following positive topline results from the company’s Phase 2b REZOLVE-AD trial of rezpegaldesleukin in patients ...

H.C. Wainwright analyst Arthur He raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating ...

Finding an effective, safe medication to control itch is essential to maximize patient comfort. Because Zenrelia does not require a loading dose and is administered once daily, Zenrelia may help impro ...

An analyst tracking the stock made a drastic change to his price target. The latest biotech stock to explode in price, Nektar ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...